Johannes O.
- Country
- Germany
- Department
- Institute of Experimental Hematology and Transfusion Medicine
Research Overview
- Pharmacokinetic Evaluation of Efanesoctocog Alfa Versus Other Extended Half-Life Recombinant Factor VIII Products in Severe Haemophilia A Patients
- Phase 1 Open‑Label Dose‑Escalation Study of Inno8 in Adults and Adolescents with Haemophilia A, With or Without Inhibitors, Assessing Pharmacokinetics and Safety
- Long-term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients with Hemophilia A or Hemophilia B: A Phase 3 Cohort Study
Data & Insights
Has run more than one trial at 64 of 127 partner sites.
Specializations
Hemophilia A Management
This investigator specializes in comprehensive treatment approaches for severe and moderate Hemophilia A, with particular focus on both prophylactic and therapeutic interventions.
- Factor VIII replacement therapy
- Extended half-life treatments
- Prophylactic protocols
Their research extends to managing FVIII inhibitors and evaluating novel therapeutic approaches for different patient populations.
Specialized Blood Disorders
The investigator's expertise encompasses various blood disorders, including Type 3 Von Willebrand Disease and Hemophilia B.
- Gene therapy applications
- Bleeding management protocols
- Long-term treatment outcomes
Their work includes evaluation of innovative therapeutic approaches for rare bleeding disorders.
Clinical Outcomes Research
The investigator focuses on assessing joint health outcomes and quality of life measures in patients with bleeding disorders.
- Physical activity assessment
- Joint health monitoring
- Long-term effectiveness studies
Their research includes evaluation of treatment efficacy in different patient demographics, including women and young patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.